[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [$tngx](/topic/$tngx) ### Top Social Posts *Showing only X posts for non-authenticated requests. Use your API key in requests for full results.* "$TNGX: Tango Therapeutics Aims for Market Entry After Clinical Validation" [X Link](https://x.com/TraderTimes_en/status/1980234051848937699) [@TraderTimes_en](/creator/x/TraderTimes_en) 2025-10-20T11:26Z XXX followers, XX engagements "Watchlist for 10/20: Bullish anticipation: $INTC $ERIC $TNGX $POWI Breakout continuation: $PGEN $GILD $SPAI 2nd day play: $RANI $ARTV Market conditions aren't ideal for momentum trades right now. There's a lack of follow-through on breakouts so staying cautious tomorrow is ke" [X Link](https://x.com/AntiFOMOTrader/status/1980134011772035118) [@AntiFOMOTrader](/creator/x/AntiFOMOTrader) 2025-10-20T04:48Z XXX followers, XXX engagements "Still like $IDYA as one of best ideas. primarily for DLL3 ADC that showed excellent data competitive with $AMGN bi engager. MAT2A inh is not competitive on efficacy with PRMT5 I from $TNGX or $BMY IDYA has not updated any single agent activity for about X years on very small sample. Doubt $RHHBY will consider it vs PRMT5. Roche chief scientist Garraway discovered SL with MTAP deletion and will likely know how to look at clinical data PKC inh likely to get approval in UM with pos upcoming trial but was expecting more from phase X ( OS XX months in comparison with 18-19 months with ipi nivo" [X Link](https://x.com/bioinvestor24/status/1980103053421564299) [@bioinvestor24](/creator/x/bioinvestor24) 2025-10-20T02:45Z 4394 followers, 3281 engagements "Top XX most SHORTed stocks with $XX M market cap: X. $XHG 3631% X. $HSDT XXX% X. $PTRN XXX% X. $BBOT XXX% X. $AIRE XXX% X. $LBRX XXX% X. $DVLT XX% X. $IBRX XX% X. $ORBS XX% XX. $BYND XX% XX. $YMM XX% XX. $HYPD XX% XX. $OMDA XX% XX. $TRON XX% XX. $ZBIO XX% XX. $TNGX XX% XX. $RKT XX% XX. $DPRO XX% XX. $DFDV XX% XX. $AEI 47%" [X Link](https://x.com/OptionAlert_ai/status/1980065954781610280) [@OptionAlert_ai](/creator/x/OptionAlert_ai) 2025-10-20T00:18Z XXX followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"$TNGX: Tango Therapeutics Aims for Market Entry After Clinical Validation"
X Link @TraderTimes_en 2025-10-20T11:26Z XXX followers, XX engagements
"Watchlist for 10/20: Bullish anticipation: $INTC $ERIC $TNGX $POWI Breakout continuation: $PGEN $GILD $SPAI 2nd day play: $RANI $ARTV Market conditions aren't ideal for momentum trades right now. There's a lack of follow-through on breakouts so staying cautious tomorrow is ke"
X Link @AntiFOMOTrader 2025-10-20T04:48Z XXX followers, XXX engagements
"Still like $IDYA as one of best ideas. primarily for DLL3 ADC that showed excellent data competitive with $AMGN bi engager. MAT2A inh is not competitive on efficacy with PRMT5 I from $TNGX or $BMY IDYA has not updated any single agent activity for about X years on very small sample. Doubt $RHHBY will consider it vs PRMT5. Roche chief scientist Garraway discovered SL with MTAP deletion and will likely know how to look at clinical data PKC inh likely to get approval in UM with pos upcoming trial but was expecting more from phase X ( OS XX months in comparison with 18-19 months with ipi nivo"
X Link @bioinvestor24 2025-10-20T02:45Z 4394 followers, 3281 engagements
"Top XX most SHORTed stocks with $XX M market cap: X. $XHG 3631% X. $HSDT XXX% X. $PTRN XXX% X. $BBOT XXX% X. $AIRE XXX% X. $LBRX XXX% X. $DVLT XX% X. $IBRX XX% X. $ORBS XX% XX. $BYND XX% XX. $YMM XX% XX. $HYPD XX% XX. $OMDA XX% XX. $TRON XX% XX. $ZBIO XX% XX. $TNGX XX% XX. $RKT XX% XX. $DPRO XX% XX. $DFDV XX% XX. $AEI 47%"
X Link @OptionAlert_ai 2025-10-20T00:18Z XXX followers, XXX engagements
/topic/$tngx/posts